USFDA Product Approval
Alembic Pharmaceuticals Receives USFDA Final Approval for Oseltamivir Phosphate Oral Suspension
NSE
aplltd
BSE
533573
Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL, a generic equivalent of Tamiflu®. The product addresses treatment and prophylaxis of influenza, with an estimated U.S. market size of US$27 million.
PRICE-SENSITIVE TRIGGER
Event: USFDA grants final approval for Alembic’s Oseltamivir Phosphate Oral Suspension ANDA.
Type: USFDA Product Approval
Impact: Neutral
Immediate Effect:Â The approval allows Alembic to commercially market the generic product in the United States, subject to normal commercial launch decisions, strengthening its U.S. generics portfolio.
Key Metrics:
- Estimated U.S. Market Size:Â US$27 million (MAT March 2026, IQVIA)
- Product Strength:Â 6 mg/mL Oral Suspension
- Total USFDA ANDA Approvals:Â 243
- Final Approvals:Â 223
- Tentative Approvals:Â 20
Highlight:
- Estimated U.S. Market Opportunity: US$27 million for the twelve months ending March 2026 (IQVIA).
What Happened ?
Alembic Pharmaceuticals announced that it has received USFDA final approval for its Abbreviated New Drug Application (ANDA) for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL.
The approved product is therapeutically equivalent to Tamiflu® Oral Suspension, 6 mg/mL of Hoffmann-La Roche Inc. Oseltamivir is a neuraminidase inhibitor indicated for the treatment of uncomplicated influenza A and B in eligible patients and for the prophylaxis of influenza in patients aged one year and above.
The approval further expands Alembic’s U.S. generic pharmaceutical portfolio while reinforcing its regulatory execution capabilities.
Key Details
Approval Highlights:
- USFDA granted final approval for Oseltamivir Phosphate Oral Suspension, 6 mg/mL.
- Product approved under the Abbreviated New Drug Application (ANDA) pathway.
- Therapeutically equivalent to the reference listed drug Tamiflu® Oral Suspension, 6 mg/mL.
- Indicated for:
- Treatment of acute, uncomplicated Influenza A and B in patients aged 2 weeks and above who have been symptomatic for no more than 48 hours.
- Prophylaxis of Influenza A and B in patients 1 year and older.
- Estimated U.S. market opportunity stands at US$27 million for the twelve months ending March 2026 according to IQVIA.
- Alembic’s cumulative USFDA approvals now total 243 ANDAs, comprising 223 final approvals and 20 tentative approvals.
Note:
- The company did not disclose the expected commercial launch timeline or anticipated revenue contribution from the approved product.
Risk Analysis
Summary:
- While the final approval enables commercialization, the financial benefit will depend on launch timing, pricing, competitive intensity and market penetration in the U.S. generic pharmaceutical market.
Key Risks:
- Competition from existing generic manufacturers.
- Pricing pressure within the U.S. generics market.
- Commercial launch timing remains undisclosed.
- Revenue contribution depends on market share and customer adoption.
Worst Case:
- Aggressive generic competition and pricing erosion could limit the commercial opportunity despite regulatory approval.
Risk Level: Low
Company Commentary
- Alembic has received USFDA final approval for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL.
- The approved product is therapeutically equivalent to Tamiflu® Oral Suspension.
- The approval strengthens Alembic’s expanding U.S. generic product portfolio.
- The company now holds 243 cumulative USFDA ANDA approvals, reflecting its continued regulatory execution.
Official Exchange Filing: Alembic Pharmaceuticals Limited
